Navigation Links
Diet and lifestyle critical to recovery, says study
Date:1/17/2008

Diet and lifestyle may play a much more significant role in a persons ability to respond favourably to certain drugs, including some cancer therapies, than previously understood, say scientists.

Writing in Nature Genetics, University of Manchester researchers have shown how the nutrients in the environment are critical to the fitness of cells that carry genetic mutations caused by diseases.

The findings for the first time provide a scientific insight into why some people might respond better to certain medications than others and form the foundations for more individualised drug therapy in the future.

The team used bakers yeast a model organism studied by biologists to reveal molecular processes in higher organisms to explore the relationship between environment and genetic background.

The large-scale study involved removing one of the two copies of all yeast genes similar to removing one parents set of genes in a human and analysing the resulting fitness under different dietary restrictions.

If the gene targeted is quantitatively important, you would normally expect the yeast to show a reduction in fitness, said Dr Daniela Delneri, who carried out the research in the Universitys Faculty of Life Sciences.

But what we found was that in certain environmental conditions, removing one copy of certain genes actually produced the opposite effect and surprisingly the yeast cells grew more quickly and were healthier.

The team further established that this effect was mainly occurring in genes involved in the proteasome the quality-control system within the cell that degrades unwanted proteins.

The proteasome is important as it maintains the equilibrium of the cell, said Dr Delneri. When this equilibrium is lost it can result in a number of diseases, including cancer, diabetes, Huntingdons, Alzheimers and Parkinsons.

For example, in rapidly-growing cancerous cells the high proteasome ac
'/>"/>

Contact: Aeron Haworth
aeron.haworth@manchester.ac.uk
44-161-275-8383
University of Manchester
Source:Eurekalert

Page: 1 2

Related biology news :

1. SAGEs American Journal of Lifestyle Medicine looks at the health benefit of oats
2. Critically endangered Amur leopard captured
3. First-ever study: lack of critical lubricant causes wear in joints
4. Rutgers scientists research reveals critical knowledge about the nervous system
5. Critically endangered porpoise is focus of new research report
6. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals
7. A study by the MUHC and McGill University opens a new door to understanding cancer
8. Study begins to reveal clues to the cause and progression of sepsis
9. Clones on task serve greater good, evolutionary study shows
10. New study warns limited carbon market puts 20 percent of tropical forest at risk
11. New study examines how rearing environment can alter navigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2008)...ed the "Evaluate the Clinical use of vitamin K Sup...ia" (ECKO) trial, Angela Cheung and colleagues at ...aily vitamin K1 supplement did not protect against...owever, as reported in this week,s PLoS Medicine ...otect against fracture and cancer in postmenopausa...
(Date:10/13/2008)...nstitute, working with collaborators at Tufts and ...rol over embryonic stem cells, behavior. The resea... within frog embryonic stem cells and trigged a ca...h, change in cell shape, and invasion of the major...signals are a powerful control mechanism that can ...
(Date:10/13/2008)...itch a ride on the wind, but a new study in the Oc...s publication, confirms that they are anything but...Biology offered the first evidence that Silver Y ...iling on favorable winds to reach their southerly ...he research team that brought us that finding reve...
(Date:10/13/2008)...ormation in the lowly fruit fly, a little molecula...al precision, according to a study in the Oct. 14 ...ospital Medical Center. , While the fundamentals...insignificant, one day they could matter quite a b...w information about how cells choose their own fat...
Breaking Biology News(10 mins):Forsyth scientists trigger cancer-like response from embryonic stem cells 2Migratory moths may hitch their rides, but they're anything but drifters 2Scientists trace molecular origin of proportional development 2Scientists trace molecular origin of proportional development 3Super Prostate Product More Beta sitosterol all natural Best Prostate 28TM 29 Formula for Enlarged Prostate and BPH Increases Urine Flow Reduces 12990 1Super Prostate Product More Beta sitosterol all natural Best Prostate 28TM 29 Formula for Enlarged Prostate and BPH Increases Urine Flow Reduces 12990 2Super Prostate Product More Beta sitosterol all natural Best Prostate 28TM 29 Formula for Enlarged Prostate and BPH Increases Urine Flow Reduces 12990 3MDS to Release First Quarter 2008 Results 12987 1FDA Issues Not Approvable Letter for Lillys Zyprexa 28R 29 Long Acting Injection 28LAI 29 for Schizophrenia Treatment 12983 1FDA Issues Not Approvable Letter for Lillys Zyprexa 28R 29 Long Acting Injection 28LAI 29 for Schizophrenia Treatment 12983 2FDA Issues Not Approvable Letter for Lillys Zyprexa 28R 29 Long Acting Injection 28LAI 29 for Schizophrenia Treatment 12983 3FDA Issues Not Approvable Letter for Lillys Zyprexa 28R 29 Long Acting Injection 28LAI 29 for Schizophrenia Treatment 12983 4FDA Issues Not Approvable Letter for Lillys Zyprexa 28R 29 Long Acting Injection 28LAI 29 for Schizophrenia Treatment 12983 5FDA Issues Not Approvable Letter for Lillys Zyprexa 28R 29 Long Acting Injection 28LAI 29 for Schizophrenia Treatment 12983 6inVentiv Health Reports Record Financial Results for Fourth Quarter and Full Year 2007 12982 1inVentiv Health Reports Record Financial Results for Fourth Quarter and Full Year 2007 12982 2inVentiv Health Reports Record Financial Results for Fourth Quarter and Full Year 2007 12982 3inVentiv Health Reports Record Financial Results for Fourth Quarter and Full Year 2007 12982 4inVentiv Health Reports Record Financial Results for Fourth Quarter and Full Year 2007 12982 5inVentiv Health Reports Record Financial Results for Fourth Quarter and Full Year 2007 12982 6inVentiv Health Reports Record Financial Results for Fourth Quarter and Full Year 2007 12982 7inVentiv Health Reports Record Financial Results for Fourth Quarter and Full Year 2007 12982 8inVentiv Health Reports Record Financial Results for Fourth Quarter and Full Year 2007 12982 9inVentiv Health Reports Record Financial Results for Fourth Quarter and Full Year 2007 12982 10inVentiv Health Reports Record Financial Results for Fourth Quarter and Full Year 2007 12982 11inVentiv Health Reports Record Financial Results for Fourth Quarter and Full Year 2007 12982 12inVentiv Health Reports Record Financial Results for Fourth Quarter and Full Year 2007 12982 13inVentiv Health Reports Record Financial Results for Fourth Quarter and Full Year 2007 12982 14inVentiv Health Reports Record Financial Results for Fourth Quarter and Full Year 2007 12982 15
...ain variants of a simple sugar ameliorate Alzheime... by Canadian researchers. Although the new studies... lead to new therapies that prevent or delay the o...w that some types of a sugar called cyclohexanehex...tion of amyloid â deposits, a hallmark of Alzheime...
...ria has been outsmarting the human immune system f...k malaria infections in live mice, researchers hav...s--using dead liver cells to cloak and transport i...liver. , Robert Ménard, a Howard Hughes Medical I...d his postdoctoral fellow, Rogerio Amino, at the I...
...archers at New York University have made chemical ...a process that has the potential to improve magnet...ts are reported in the latest issue of Nano Letter...rtment of Chemistry and the Department of Radiolog... of a collaborative discussion group between these...
...new interdisciplinary technology approach, develop...Italy with funding from the European Commission,s ...of the IST programme, will ultimately lead to elec...that could be used not only in healthcare but also...n or security. , "The potential uses of smell tech...
Other Biology News:A sweet solution for Alzheimer's disease? 2A sweet solution for Alzheimer's disease? 3Movie spies on malaria parasite's sneaky behavior 2Movie spies on malaria parasite's sneaky behavior 3NYU researchers decorate virus particles, showing potential to enhance MRI capabilities 2Smell of success for nanobiosensors 2
(Date:10/14/2008)... China, Oct. 14 /Xinhua--,C...ina-Biotics", "the,Company"), a leading Chinese fi...lopment, marketing and distribution of probiotics ... to list its common stock on the,Nasdaq Global Mar...he Nasdaq on October 23,2008, until which time it...
(Date:10/14/2008)... Va., Oct. 14 /- Insmed Inc...ogics and biopharmaceuticals, today,announced that...reverse,stock split, if necessary, at a Special Me...effort to meet the minimum bid price rule for cont...tember 3, 2008, the Company announced that the NAS...
(Date:10/14/2008)... China, Oct. 14 /Xinhua-- WuXi Pharma...eutical, biotechnology and,medical device research...ns,in China and the United States, today announced...for the third quarter ended September 30, 2008,an...Logo: http://www.newscom.com/cgi-bin/prnh/2004070...
(Date:10/13/2008)...ES, Oct. 13 /- Vista Partners announc...can Bio Medica Corporation,(Nasdaq: ABMC ) and ma...ss,Silver, Director of Research at Vista Partners ...e and sales from the Company,s lab,alliance, which... centers,continue to increase as well. The Compan...
Breaking Biology Technology:China-Biotics, Inc. Approved to List on the Nasdaq Global Market 2Insmed to Seek Shareholder Approval for Reverse Split 2Insmed to Seek Shareholder Approval for Reverse Split 3WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance 2WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance 3WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance 4WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance 5WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance 6WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance 7WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance 8Vista Partners Updates Coverage; Maintains $3.20 Target Price 2
..., , , , , , The programming ...ent PCR program, and provides addtional explanatio... , , , , , , ... Explanation, , , ... Temperature control for the , block....
..., , , , , , 7.6.3 Touch Dow...t, which can be programmed as desired with every ,...e to be reduced or increased by , a defined...Down PCR can be used to increase the specificity o...emperature in succession from higher to lower temp...
..., , , , , , Joel Lopez and ...s Laboratory, Brinkmann Instruments Inc., Westbury...roduction , Science underwent revolution... in the field of genetics. One of the most sig...85 article by Saiki, et al, in which the amplifica...
...nsional Optimization of a Semi-nested PCR , ... , , , , , Andrea Tanzer an...ute of Milk Hygiene, Milk Technology and Food Scie...ppendorf AG, Germany, , , , , ,...es, which are triggered by contaminated foodstuffs...
Other Biology Technology:Title 2Two-step Gradient PCR* 2Two-step Gradient PCR* 3Two-step Gradient PCR* 4Two-step Gradient PCR* 5Two-step Gradient PCR* 6Two-dimensional Optimization of a Semi-nested PCR, for Detecting Listeria monocytogenes 2Two-dimensional Optimization of a Semi-nested PCR, for Detecting Listeria monocytogenes 3Two-dimensional Optimization of a Semi-nested PCR, for Detecting Listeria monocytogenes 4Two-dimensional Optimization of a Semi-nested PCR, for Detecting Listeria monocytogenes 5Two-dimensional Optimization of a Semi-nested PCR, for Detecting Listeria monocytogenes 6Two-dimensional Optimization of a Semi-nested PCR, for Detecting Listeria monocytogenes 7
Mouse monoclonal antibody raised against a partial recombinant VRK2. NCBI Entrez Gene ID = VRK2
Mouse monoclonal antibody raised against a partial recombinant L3MBTL2. NCBI Entrez Gene ID = L3MBTL2
Mouse polyclonal antibody to BAG2 - BCL2-associated athanogene 2
Mouse monoclonal antibody raised against a partial recombinant IFNA2. Immunogen: Human IFNA2 (NP_000596, 24 a.a.-188 a.a.) partial recombinant protein is produced in E. coli. The biological act
Biology Products: